Viva Biotech Holdings (VBIZF)
OTCMKTS
· Delayed Price · Currency is USD
0.2270
0.00 (0.00%)
At close: Apr 14, 2025
Viva Biotech Holdings Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| Revenue | 1,987 | 2,156 | 2,380 | 2,104 | 696.96 | Upgrade
|
| Revenue Growth (YoY) | -7.84% | -9.41% | 13.10% | 201.89% | 115.74% | Upgrade
|
| Cost of Revenue | 1,299 | 1,417 | 1,564 | 1,453 | 392.09 | Upgrade
|
| Gross Profit | 687.4 | 738.43 | 815.68 | 650.98 | 304.87 | Upgrade
|
| Selling, General & Admin | 364.12 | 409.66 | 404.45 | 320.29 | 123.26 | Upgrade
|
| Research & Development | 87.99 | 127.97 | 135.84 | 92.38 | 66.04 | Upgrade
|
| Other Operating Expenses | - | - | 3.37 | - | 3.03 | Upgrade
|
| Operating Expenses | 457.73 | 545.75 | 549.7 | 414.08 | 192.33 | Upgrade
|
| Operating Income | 229.67 | 192.68 | 265.98 | 236.9 | 112.54 | Upgrade
|
| Interest Expense | -53.89 | -176.58 | -184.67 | -183.11 | -62.13 | Upgrade
|
| Interest & Investment Income | 20.54 | 27.38 | 21.61 | 26.58 | 16.71 | Upgrade
|
| Earnings From Equity Investments | -0.1 | - | - | - | -0.49 | Upgrade
|
| Currency Exchange Gain (Loss) | 16.18 | -51.01 | -146.39 | 31.41 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 32.7 | 210.93 | -4.33 | 188.05 | -542.14 | Upgrade
|
| EBT Excluding Unusual Items | 245.1 | 203.39 | -47.81 | 299.83 | -475.51 | Upgrade
|
| Gain (Loss) on Sale of Investments | 91.12 | -11.68 | -364.18 | 55.16 | 113.24 | Upgrade
|
| Gain (Loss) on Sale of Assets | -1.91 | 0.28 | -1.9 | -5.2 | 1.61 | Upgrade
|
| Asset Writedown | -38.61 | -25.19 | -6.57 | -2.1 | - | Upgrade
|
| Other Unusual Items | - | -222.76 | -38.7 | - | 4.45 | Upgrade
|
| Pretax Income | 295.71 | -55.95 | -459.17 | 347.7 | -356.21 | Upgrade
|
| Income Tax Expense | 73.72 | 43.84 | 45.06 | 47.14 | 22.66 | Upgrade
|
| Earnings From Continuing Operations | 221.99 | -99.79 | -504.22 | 300.56 | -378.87 | Upgrade
|
| Minority Interest in Earnings | -54.69 | -16.32 | -24.26 | -13.01 | -8.01 | Upgrade
|
| Net Income | 167.29 | -116.11 | -528.48 | 287.55 | -386.88 | Upgrade
|
| Net Income to Common | 167.29 | -116.11 | -528.48 | 287.55 | -386.88 | Upgrade
|
| Shares Outstanding (Basic) | 2,137 | 1,940 | 1,915 | 1,912 | 1,572 | Upgrade
|
| Shares Outstanding (Diluted) | 2,868 | 2,029 | 1,915 | 1,971 | 1,572 | Upgrade
|
| Shares Change (YoY) | 41.39% | 5.91% | -2.81% | 25.41% | 5.83% | Upgrade
|
| EPS (Basic) | 0.08 | -0.06 | -0.28 | 0.15 | -0.25 | Upgrade
|
| EPS (Diluted) | 0.06 | -0.14 | -0.28 | 0.08 | -0.25 | Upgrade
|
| Free Cash Flow | - | 195.73 | 136.72 | -487.35 | -549.44 | Upgrade
|
| Free Cash Flow Per Share | - | 0.10 | 0.07 | -0.25 | -0.35 | Upgrade
|
| Dividend Per Share | - | - | - | - | 0.023 | Upgrade
|
| Dividend Growth | - | - | - | - | 29.28% | Upgrade
|
| Gross Margin | 34.60% | 34.26% | 34.28% | 30.94% | 43.74% | Upgrade
|
| Operating Margin | 11.56% | 8.94% | 11.18% | 11.26% | 16.15% | Upgrade
|
| Profit Margin | 8.42% | -5.39% | -22.21% | 13.67% | -55.51% | Upgrade
|
| Free Cash Flow Margin | - | 9.08% | 5.75% | -23.16% | -78.83% | Upgrade
|
| EBITDA | 428 | 391.01 | 436.35 | 369.94 | 164.35 | Upgrade
|
| EBITDA Margin | 21.54% | 18.14% | 18.34% | 17.58% | 23.58% | Upgrade
|
| D&A For EBITDA | 198.33 | 198.33 | 170.37 | 133.04 | 51.81 | Upgrade
|
| EBIT | 229.67 | 192.68 | 265.98 | 236.9 | 112.54 | Upgrade
|
| EBIT Margin | 11.56% | 8.94% | 11.18% | 11.26% | 16.15% | Upgrade
|
| Effective Tax Rate | 24.93% | - | - | 13.56% | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.